Biogen to Sell Rights to Psoriasis Drug AP via Yahoo! Finance - Apr 03 1:43 PM Biotech company Biogen Idec Inc. said Monday it agreed to sell the worldwide rights of Amevive, a psoriasis treatment, to the U.S. arm of Japanese drug maker Astellas Pharma Inc., for $60 million.Save to My Web
Read The Full Article:
http://www.drilltools.org/297
Add to del.icio.us
Digg this
Post to Furl
Add to reddit
Add to myYahoo!
Powered by blogdig.net